Next Article in Journal
Magnetic Scaffolds for Bone Cancer Theranostics
Previous Article in Journal
Simulation of Indirect 13C–13C J-Coupling Tensors in Diamond Clusters Hosting the NV Center
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Abstract

Carbon Nanomaterials as Promising Carriers of Cytostatic Drugs in Cancer Chemotherapy: Pilot Study †

by
Vladimir A. Shipelin
1,*,
Ivan V. Gmoshinski
1,
Nikolay A. Riger
2,
Antonina A. Shumakova
1,
Eleonora N. Trushina
2,
Oksana K. Mustafina
2 and
Sergey A. Khotimchenko
1
1
Laboratory of Food Toxicology and Safety Assessment of Nanotechnology, Federal Research Centre of Nutrition and Biotechnology, 109240 Moscow, Russia
2
Laboratory of Immunology, Federal Research Centre of Nutrition and Biotechnology, 109240 Moscow, Russia
*
Author to whom correspondence should be addressed.
Presented at the 3rd International Online-Conference on Nanomaterials, 25 April–10 May 2022; Available online: https://iocn2022.sciforum.net.
Mater. Proc. 2022, 9(1), 6; https://doi.org/10.3390/materproc2022009006
Published: 24 April 2022
(This article belongs to the Proceedings of The 3rd International Online-Conference on Nanomaterials)

Abstract

:
Carbon nanomaterials (CNMs), such as single-walled (SWCNTs) carbon nanotubes, multi-walled carbon nanotubes (MWCNTs), and fullerene derivatives, are considered promising agents for the delivery of pharmacological drugs to target organs, including antitumor chemotherapy and theranostics. However, the question arises about CNMs’ possible effects on the general toxic and immunotoxic effects of cytostatic preparations when they are administered mutually. This work aimed to study the combined effects of cyclophosphamide (CP) intoxication and oral CNM administration in male Wistar rats. In two experiments lasting 16 and 35 days, MWCNTs, SWCNTs, or polyhydroxylated fullerenol (PHF60) were administered to control or treat CP rats, at a dose of 0.1 mg/kg of body weight daily prepared as dispersions in drinking water. The lethality and integral parameters of the rats were assessed; the content of erythrocytes and leukocytes, biochemical indicators, levels of cytokines, chemokines, and growth factors was measured. In the first experiment lasting 16 days, the consumption of both MWCNTs and SWCNTs led to an almost two-fold decrease in mortality caused by the administration of CP. In the second experiment lasting 35 days, a similar decrease in mortality was noted for SWCNTs; the capability of MWCNTs and PHF60 to increase the survival of animals was also pronounced. The administration of MWCNTs, SWCNTs, and PHF60 to the animals reduced the immunotoxic effects of CP, resulting in increased lymphocyte counts and a correction of the imbalance between cytokines and chemokines/growth factors, including IL-4, IL-13, IL-17A, IFN-g, IL-18, GM -CSF, GRO-KC, IL-12p70, IL-1b, IL-7, TNF-a, and VEGF. Thus, various CNMs, when administered together with CP, caused a partial abolition of their general toxic and immunotoxic action, which can be explained by the available literature data on the ability of CNMs to enhance the mobilization, migration, and adhesion of blood cells and trigger immune responses.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/materproc2022009006/s1.

Author Contributions

Conceptualization, S.A.K. and I.V.G.; methodology, V.A.S.; validation, V.A.S., I.V.G. and A.A.S.; formal analysis, I.V.G. and V.A.S.; investigation, V.A.S., I.V.G., N.A.R., A.A.S., E.N.T. and O.K.M.; resources, V.A.S. and A.A.S.; data curation, I.V.G. and S.A.K.; writing—original draft preparation, I.V.G. and V.A.S.; writing—review and editing, S.A.K.; visualization, I.V.G. and V.A.S.; supervision, I.V.G.; project administration, S.A.K.; funding acquisition, S.A.K. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Ministry of Education and Science of the Russian Federation grant number 0410-2022-0003.

Institutional Review Board Statement

The animal study protocol was approved by the Institutional Ethics Committee of the Federal Research Centre of Nutrition and Biotechnology (protocol code # 4, 20 April 2017).

Informed Consent Statement

Not applicable.

Data Availability Statement

The datasets generated during the current study are available from the corresponding author on reasonable request by email.

Conflicts of Interest

The authors declare no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Shipelin, V.A.; Gmoshinski, I.V.; Riger, N.A.; Shumakova, A.A.; Trushina, E.N.; Mustafina, O.K.; Khotimchenko, S.A. Carbon Nanomaterials as Promising Carriers of Cytostatic Drugs in Cancer Chemotherapy: Pilot Study. Mater. Proc. 2022, 9, 6. https://doi.org/10.3390/materproc2022009006

AMA Style

Shipelin VA, Gmoshinski IV, Riger NA, Shumakova AA, Trushina EN, Mustafina OK, Khotimchenko SA. Carbon Nanomaterials as Promising Carriers of Cytostatic Drugs in Cancer Chemotherapy: Pilot Study. Materials Proceedings. 2022; 9(1):6. https://doi.org/10.3390/materproc2022009006

Chicago/Turabian Style

Shipelin, Vladimir A., Ivan V. Gmoshinski, Nikolay A. Riger, Antonina A. Shumakova, Eleonora N. Trushina, Oksana K. Mustafina, and Sergey A. Khotimchenko. 2022. "Carbon Nanomaterials as Promising Carriers of Cytostatic Drugs in Cancer Chemotherapy: Pilot Study" Materials Proceedings 9, no. 1: 6. https://doi.org/10.3390/materproc2022009006

Article Metrics

Back to TopTop